Haiyan Tang is a partner in the Litigation Department of Paul Hastings and is based in the firm’s Shanghai Office. Her practice focuses on advising multinational companies in their global government enforcement, investigation, and compliance matters and advising China-based companies in sensitive cross-border litigation and arbitration.
Ms. Tang regularly advises clients in a wide variety of industries on their high-profile U.S. and Chinese government enforcement actions and internal investigations involving corruptions, financial fraud, antitrust and competition issues, government sanctions, and trade policies. She is a top expert in designing and assessing compliance programs, having led the development of many high-standard compliance programs for companies operating in the complex Chinese‑business environment. Ms. Tang conducted compliance due diligence projects for many top private equity firms and investment banks on their high-stakes, fast-paced investments. She has extensive litigation experience in the U.S. and has helped many top companies to win high stake cross-border litigation and arbitration battles.
Prior to joining Paul Hastings, Ms. Tang served as Managing Director and Chief Legal & Compliance Officer of a leading private equity fund focusing on health care investment in Asia. She has established compliance programs, led litigations, managed corporate transactions, and designed intellectual property strategies for the fund and its portfolio companies. Ms. Tang actively participates in business decision process and has intimate knowledge on the operation of a private equity fund and legal compliance needs of different stages of pharmaceutical, medical device companies, and hospitals.
Ms. Tang was the Acting Regional Compliance Director of a leading global pharmaceutical company when it was fulfilling its self-reporting obligation to the United States Department of Justice, and the United States Securities and Exchange Commission, managing the Company’s China investigations, participating in proactive compliance reviews, working with multiple stakeholders to remediate issues identified in investigations, and developing compliance strategies. She has also worked for a top international law firm’s Silicon Valley office for four years.
Ms. Tang was awarded the Paul Grossman Coaching Award in 2019, for building a highly effective litigation and investigation team in Shanghai that is praised by clients across different sectors. She was recognized as one of 100 top female practitioners in the field worldwide by Global Investigations Review in its Women recognized by Global Investigations Review in its Women in Investigations 2018 special edition, highlighting 100 female practitioners in this profession. She was also recognized by the Chambers Asia-Pacific 2019 as a “Recommended Attorney.”
Investigations and Government Enforcement
Compliance Programs, Due Diligence, and Risk Assessment
Litigations and Arbitrations
Private Equity Fund Legal and Compliance
Ms. Tang is a co-author of the following publications:
Ms. Tang was a speaker at the following conferences:
Paul Hastings Named to World’s Top 10 Best Investigations Practices by Global Investigations Review
October 23, 2020
Paul Hastings Recognized at China Law & Practice Awards 2020
October 19, 2020
Paul Hastings Welcomes High-Profile Litigation Partner Haiyan Tang Back to the Firm
August 10, 2020
China Enacts New Export Control Law – Global Businesses Take Heed
November 02, 2020
China Enacts Regulations on Unreliable Entity List
September 22, 2020
Commerce Simplifies—but Expands—the Foreign Direct Product Rule for Huawei
August 19, 2020
Nine Things You Need to Know About the Trump Administration Sanctions Against TikTok and WeChat
August 10, 2020
Does Your Research Compliance Need a Refresh? China’s Highest Court Sends a Warning to Life Sciences Companies
October 09, 2017
China’s New Cybersecurity Regime
April 19, 2017
Recent Developments Strengthen Chinese Anti-Bribery Law
May 19, 2016
China Releases New Regulations on Donations to Healthcare Entities: Implications for Multinational Healthcare Companies
November 10, 2015
Paul Hastings Point of View: Why are Chinese companies running afoul of U.S. Laws?
July 10, 2015
Recent Developments in U.S. Investigations and Litigation
May 07, 2015
Legislative Reform of China’s Healthcare Sector Targets Corruption: Implications for Multinational Companies
August 28, 2014
Recognized among the World’s Top 10 Best Investigations Practices by Global Investigations Review for 2020
Paul Hastings ranked in the Top 10 of Global Investigations Review’s GIR 100, an annual guide to the world’s leading cross border investigations practices. The citation reads in part: “Few firms can boast the breadth of experience that Paul Hastings can. GIR data shows that Paul Hastings is listed as having advised on more FCPA settlements than any other firm since late 2008, and has had more FCPA monitorships than any other firm since 2004."
The following attorneys were noted in the profile based on their exceptional performance across the white collar practice: Kwame Manley, Tara Giunta, Gary Giampetruzzi, Thomas Zaccaro, Robert Luskin, John S. (Jay) Darden, Nat Edmonds, Tim Dickinson, Morgan Miller, Corinne Lammers, Nicola Bonucci, Simon Airey, Tom Best, Matt Herrington, Jonathan Drimmer, Peter Axelrod, Shaun Wu, Jason Fiebig, and Haiyan Tang.
October 23, 2020
Recognized by Chambers Global 2019
Chambers Global 2019: The World’s Leading Lawyers listed the firm in 37 research areas and named 59 firm lawyers to its rankings of leading lawyers and law firms adept in complex international work and with strong cross-border capabilities.
February 14, 2019
Recognized by Global Investigations Review among Top Women in Investigations
Haiyan Tang was recognized by Global Investigations Review (GIR) in its Women in Investigations list, which recognized 100 women across the globe who are “achieving great things in a competitive and notoriously tough area of law."
June 01, 2018